Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT-803

NCT02890758 is registered in ClinicalTrials.gov with Brenda Cooper, MD as lead sponsor.

NCT NCT02890758
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02890758 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT-803
Lead sponsor
Brenda Cooper, MD
Phase
Phase 1
Overall status
Completed
Start date
May 22, 2018
Completion date
February 17, 2023
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, acute myeloid leukemia, adenocarcinoma of rectum, chronic lymphocytic leukemia, chronic myeloid leukemia, colon carcinoma, ewing's sarcoma, hodgkin lymphoma, myelodysplastic syndrome, myeloproliferative syndromes, non hodgkin lymphoma, plasma cell myeloma, rhabdomyosarcoma, soft tissue sarcoma